THE WOODLANDS, Texas, June 15, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announces today the appointment of Stanley H. Appel, M.D. as Chairman of the Scientific Advisory Board of the Company. Dr. Appel currently holds the position of Chairman of the Department of Neurology at Baylor College of Medicine and has been instrumental in Power3's ongoing clinical validation for its neurodegenerative diagnostic test.
Prior to joining Baylor College of Medicine in 1977, Dr. Appel was Chief of Neurology and James B. Duke Professor of Medicine (Neurology) at Duke University. He is currently Director of the Jerry Lewis Neuromuscular Disease Research Center, Director of the Vicki Appel MDA/ALS Center, and Director of the Baylor Alzheimer's Disease Research Center. He is a member of the Board of Directors of Muscular Dystrophy Association. Dr. Appel is an expert and opinion leader on degenerative neurological diseases, such as Parkinson's, Alzheimer's, and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. He has published over 300 papers and 10 books in neurology and neurodegenerative diseases. Dr. Appel has received numerous honors and awards including the Colombia College of Physicians and Surgeons, Gold Medal award for excellence in Biomedical Research in 1997 and the Sheila Essey Award for ALS research from the American Academy of Neurology in 2003. He was also elected a fellow in the American Association for the Advancement of Science in 2003.
Dr. Ira Goldknopf, Chief Scientific Officer, Power3 Medical commented, "We are very pleased to have Dr. Appel as the Chairman of our Scientific Advisory Board. We are confident he will contribute incalculably to our proteomic research in the areas of neurodegenerative biomarker identification and our early detection neurodegenerative disease blood test. With his background and influence in the neurological discipline, we anticipate our collaborative efforts and technology to move forward at a rapid pace."
According to Dr. Stan Appel, "I take great pleasure in assuming the role of Chairman of Power3 Medical's Scientific Advisory Board. With the knowledge and technology that I have seen come from their operations and specifically our collaborative efforts, I am excited to partake in the development of a pioneering proteomics company."
About Power3 Medical Products, Inc.
Power3 Medical Products is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company is in a strong competitive position with over 190 validated biomarkers and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.